1309980-29-7Relevant articles and documents
COMPOUNDS AND THEIR METHODS OF USE
-
, (2020/12/13)
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.
Investigation of (E)-3-[4-(2-oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic acids as oral selective estrogen receptor down-regulators
Degorce, Sébastien L.,Bailey, Andrew,Callis, Rowena,De Savi, Chris,Ducray, Richard,Lamont, Gillian,MacFaul, Philip,Maudet, Mickael,Martin, Scott,Morgentin, Rémy,Norman, Richard A.,Peru, Aurélien,Pink, Jennifer H.,Plé, Patrick A.,Roberts, Bryan,Scott, James S.
supporting information, p. 3522 - 3533 (2015/05/05)
A novel estrogen receptor down-regulator, 7-hydroxycoumarin (5, SS5020), has been reported with antitumor effects against chemically induced mammary tumors. Here, we report on our own investigation of 7-hydroxycoumarins as potential selective estrogen rec